Short Interest in Hypera S.A. (OTCMKTS:HYPMY) Rises By 33,554.8%

Hypera S.A. (OTCMKTS:HYPMY - Get Free Report) was the target of a significant growth in short interest during the month of October. As of October 15th, there was short interest totalling 2,086,600 shares, a growth of 33,554.8% from the September 30th total of 6,200 shares. Based on an average daily volume of 2,231,900 shares, the days-to-cover ratio is currently 0.9 days.

Hypera Stock Performance

OTCMKTS:HYPMY traded down $0.37 during mid-day trading on Friday, hitting $4.60. 7,694 shares of the company's stock traded hands, compared to its average volume of 85,246. The company has a fifty day moving average of $5.06 and a 200 day moving average of $5.33. Hypera has a twelve month low of $3.83 and a twelve month high of $7.90. The company has a market capitalization of $2.91 billion, a P/E ratio of 8.45 and a beta of 1.04.

Hypera (OTCMKTS:HYPMY - Get Free Report) last issued its quarterly earnings results on Thursday, July 25th. The company reported $0.15 earnings per share (EPS) for the quarter. The company had revenue of $420.00 million for the quarter.

About Hypera

Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.